<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21726">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943812</url>
  </required_header>
  <id_info>
    <org_study_id>Skive-2013-BA</org_study_id>
    <nct_id>NCT01943812</nct_id>
  </id_info>
  <brief_title>Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation</brief_title>
  <official_title>Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Humaidan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare two FET protocols by modifying the substituted FET cycle
      in order to maintain a higher ongoing positive pregnancy rate and thus reduce the early
      pregnancy loss.

      Hypothesis: adding GnRH-agonist to the substituted cycle in FET treatment reduces the early
      pregnancy loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pregnancy loss rate</measure>
    <time_frame>Primary outcome is avaible after 12th  week of gestational.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>14 days after embryo transfer.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Luteal progesterone levels</measure>
    <time_frame>7th week of gestation</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">722</enrollment>
  <condition>Pregnancy Loss</condition>
  <condition>Frozen Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>Estradiol and progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substituted FET GnRH-a, Estradiol, Progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substituted FET cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>substituted FET cycle Estradiol Progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone and estradiol</intervention_name>
    <arm_group_label>Estradiol and progesterone</arm_group_label>
    <arm_group_label>Substituted FET cycle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endometrial thickness â‰¥ 7 mm after stimulation

          -  18-45 years

          -  IVF/ICSI fertilisation

          -  BMI &gt; 18,5 &lt;30 kg/m2

          -  cycle length 25-34 days

        Exclusion Criteria:

          -  endometrial thickness &lt; 7 mm or no triple layer endometrium and/or functional
             follicles

          -  Uterine abnormality

          -  Chronic medical disease

          -  oocyte donation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Alsbjerg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fertility Clinic Regional Hospital Skive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgit Alsbjerg, M.D.</last_name>
    <phone>+45 78 44 57 60</phone>
    <email>birgit.alsbjerg@viborg.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Humaidan, D.M.Sc.</last_name>
    <phone>+45 78 44 57 60</phone>
    <email>peter.humaidan@viborg.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVF syd</name>
      <address>
        <city>Fredericia</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steen B Laursen, Ph.D.</last_name>
      <phone>+45 76 24 50 20</phone>
    </contact>
    <investigator>
      <last_name>Steen B Lauersen, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic Regional Hospital Skive</name>
      <address>
        <city>Skive</city>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Alsbjerg, M.D.</last_name>
      <phone>+45 78 44 57 60</phone>
    </contact>
    <investigator>
      <last_name>Birgit Alsbjerg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>D.M.Sc., M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
